Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com -- Bure Equity AB (ST:BURE) reported a sharp decline in its first-half 2025 results, with net asset value (NAV) per share down 16.5% to SEK 277.9 from SEK 333.0 at the start of the year, reflecting a drop in NAV to SEK 20.6 billion from SEK 24.7 billion.
The total return on the Bure share was -24.8%, compared with a 2.5% rise in the SIX Return Index.
Group earnings after tax came in at SEK -3.88 billion, compared with a profit of SEK 4.75 billion a year earlier, translating to earnings per share of SEK -52.4.
In the second quarter, NAV per share fell 6.6% from the start of the period, as key holdings Yubico, Vitrolife and Mycronic saw share price declines, with Yubico dropping nearly 20% and Vitrolife 13%.
Among portfolio companies, Mycronic delivered a strong report and raised its full-year forecast, while Ovzon surged 74% during the quarter on a landmark SEK 1 billion order from the Swedish Defence Materiel Administration.
Bure was active on the transaction front, signing an agreement to acquire 17% of MEMS foundry leader Silex Microsystems for SEK 917 million, and increasing its Cavotec stake to 40.7% for SEK 93 million.
The company also sold 0.9 million Ovzon shares for SEK 32 million and paid an ordinary dividend of SEK 2.75 per share.
CEO Henrik Blomquist noted that the quarter opened with market volatility due to U.S. tariff moves but recovered after a delay in their introduction.
He said Bure’s NAV performance was “weak during the quarter” due to declines in several holdings, but described Silex as “an exciting addition” with a strong growth track record and significant potential under Swedish majority ownership.